Hanbury FZE
  • Search
  • Home
  • Products & Services
    • Nutraceutical Ingredients
      • Standardized Phyto Extracts
      • Beverage/Liquid Dietary Supplements
      • GRAS Affirmed Ingredients
      • Minerals for Nutritional Use
      • Phytochemicals for Nutritional Use
      • Multi-enzyme Blends
      • Natural Protein
      • Nutritional Fine Chemicals
      • Phyto Functional Blends
      • Geroceuticals™
      • Prebiotics, Probiotics, Postbiotics and Synbiotics
      • Super Critical Fluid (SCF) Extracts
      • Specialty Fine Chemicals
    • Cosmeceutical Ingredients
      • Natural Actives
      • Peptides
      • Anti-Glycation
      • Dermaceuticals
      • Nutricosmetics
      • Probiotics & Postbiotics
      • Proprietary Cosmeceutical Blends
      • Speciality Chemicals
    • Services
      • Custom Manufacturing
      • Contract Manufacturing
      • Product Specification Sheet
    • Pharma
      • Natural Drugs
      • Chiral Drug Intermediates
  • About Us
    • Our Story
    • Our People
    • Research & Development
    • Manufacturing Facilities
    • Intellectual Properties
  • Newsroom
    • Press Release
    • FAQs
      • BioPerine®
      • Citrin®K
      • Cococin™
      • Curcumin C3 Complex®
      • Curcumin C3 Reduct®
      • ForsLean®
      • GarCitrin®
      • LactoSpore®
      • LeanGard®
  • Contact Us

Home / Sabinsa Issued New U.S. Patent for LactoSpore® Based upon Published Research Confirming Ability to Reverse Depression Symptoms in Patients Suffering from IBS

Sabinsa Issued New U.S. Patent for LactoSpore® Based upon Published Research Confirming Ability to Reverse Depression Symptoms in Patients Suffering from IBS

Sabinsa Issued New U.S. Patent for LactoSpore® Based upon Published Research Confirming Ability to Reverse Depression Symptoms in Patients Suffering from IBS

Sabinsa has been granted U.S. patent US10166261 for a method of managing dementia and dementia-related sleep disorders presented as symptoms of major depressive disorder (MDD) in humans associated with Irritable Bowel Syndrome (IBS) by administering Bacillus coagulans MTCC 5856 (LactoSpore®) at a dose of 2 billion colony forming units per day.

The patent application was supported by a recent clinical study, published in the peer-reviewed journal Food & Nutrition Research “Bacillus coagulans MTCC 5856 for the management of major depression with irritable bowel syndrome: a randomised, doubleblind, placebo controlled, multi-centre, pilot clinical study,” shelf-stable probiotic LactoSpore was reported to reduce depression symptoms in adults with IBS.

sabinsa lactospore

In a previously granted patent (US9579352), LactoSpore demonstrated that it alleviates the symptoms of IBS administered once a day, along with standard treatment of care. This latest patent, however, discloses the standalone effect of LactoSpore in improving the symptoms of IBS, along with the associated symptoms of MDD without co-administration of drugs, confirming that LactoSpore, by itself, is effective in managing psychological conditions associated with disorders in the gut, opening up a new avenue of research in the field of enteric-neurobiology and brain-gut-microbiome axis.

“It is gratifying that the US patent office recognized the strain specific action of Sabinsa’s MTCC 5856 in allowing the claims,” said Shaheen Majeed, President Worldwide, Sabinsa. “We anticipate being granted patents on the discovery in additional countries in the near future.”

The study may be accessed here: https://doi.org/10.29219/fnr.v62.1218

Back
top

HEADQUARTERS

Hanbury FZE


Jebel Ali Free Zone


Warehouse No. RA08AB05


P O Box. 61091


Dubai


United Arab Emirates


+971 4 883 8981

+971 4 883 8978

mail@hanburyfze.ae

CERTIFICATES

Certificate Logos Certificate Logos Certificate LogosCertificate Logos

Global Contacts List

USA India
Utah, USA Japan
Australia Poland
Brasil Korea
Canada South Africa
China Vietnam
Germany  

CONTACT US

    © 2023 Hanbury FZE. All Rights Reserved | Powered by Edkal Technologies | Privacy Policy | Terms of Use | Sitemap | Disclaimer

    • Facebook
    • Twitter
    • LinkedIn
    Disclaimer

    US-FDA: This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

    Usage disclaimer: The information pertaining to any marketing materials by Sabinsa, is for general purposes only. Users are urged to check the validity of patents if any, on any Sabinsa items for their intended use.

    EFSA: This statement has not been evaluated by the EFSA. This product is not intended to diagnose, treat, cure, or prevent any disease.

    Australia: Please note as an ingredient supplier the information contained in this website is for marketers of finished products formulations and is not intended as consumer advice. Marketers should ensure finished products are lawful and comply with the regulations of the countries in which these items are sold. Every care has been taken to ensure the accuracy of the information provided at the time of publication.